TrialJournal for immunotherapy of cancer2023

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.

Elisa A Rozeman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.